Medigene AG / Medigene participates at six national and international conferences . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 4 November 2016. Medigene AG (http://www.medigene.de) (MDG1, Frankfurt, Prime Standard) announces its participation at six upcoming scientific, investor and business development conferences:
- BioEurope
Date: 7 - 9 November 2016
Location: Cologne, Germany
- SITC 2016 - Society for Immunotherapy of Cancer
Date: 9 - 13 November 2016
Location: National Harbor, Maryland, USA
- Neoantigens Summit
Date: 15 - 17 November 2016
Location: Boston, USA
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk on the topic: "Are we Limited to Treatment of Tumors with High-Mutational Loads and Patients with Pre-Existing Neoantigen-Specific T Cells?"
- 6th Munich Biomarker Conference
Date: 29 - 30 November 2016
Location: Munich, Germany
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a keynote talk on the topic: "From personalized to individualized medicine, the next major step in developing the medicine of the future".
- EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Date: 29 November - 2 December 2016
Location: Munich, Germany
- ASH 2016 - The 58th American Society of Hematology Annual Meeting
Date: 3 - 6 December 2016
Location: San Diego, USA
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com (http://www.medigene.com)
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com (mailto:investor@medigene.com)
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com (mailto:investor@medigene.com)). We will then delete your address from our distribution list.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
